Received Apr 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | 1 | U8335AA | IM / RL |
| PNC20 | PNEUMO (PREVNAR20) | PFIZER\WYETH | 1 | MH1445 | IM / LL |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | 1 | 21552257 | PO / MO |
The infant developed a small subcutaneous nodule in the first few days following the vaccine administration at 2 months of age. The nodule was persistent at 4 months of age. It is felt that the nodule likely represents a post-vaccination granuloma. No infant impairment noted. No treatment was deemed necessary at this time. Outcome is expected to be favorable with possible resolution and with potentially a small cosmetic concern if the nodule does not resolve.
None
None
None
None
None